Genomma Lab Internacional, S.A.B. de C.V.

85 articles about Genomma Lab Internacional, S.A.B. de C.V.

• Genomma Lab Internacional S.A.B. de C.V. First Quarter 2024 Earnings Results Conference Call

  4/4/2024

  Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company") today announced that it will report its First Quarter 2024 Earnings Results on Wednesday, April 24, 2024, after the Mexican Stock Exchange (BMV) close. 

• Genomma Lab Internacional Announces Seventh Dividend Payment - March 13, 2024

  3/13/2024

  Genomma Lab Internacional, S.A.B. de C.V. informs that the Company filed a Notice of Rights with the Mexican Stock Exchange declaring a cash dividend of $0.196080 Mexican pesos per share on its common stock representing a total amount of $200,001,600.00 M.N., payable to shareholders of record of the applicable circulating shares at the close of business on March 25, 2024.

• Genomma Lab's ESG Rating Upgraded to A

  2/29/2024

  Genomma Lab Internacional, S.A.B. de C.V. announced that MSCI, one of the world's largest providers of indices for tracking companies according to environmental, social and governance criteria, upgraded Genomma's MSCI ESG Rating to A from BBB.

• Effects of Argentina Hyperinflationary Accounting on Q4 and Full Year 2023 Results

  2/15/2024

  Genomma Lab Internacional, S.A.B. de C.V., one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, provides a preliminary overview of 2023 full year performance relative to hyperinflationary accounting for its Argentina subsidiary.

• Genomma Lab Internacional Announces Sixth Dividend Payment - December 14, 2023

  12/14/2023

  Genomma Lab Internacional, S.A.B. de C.V. informs that the Company filed a Notice of Rights with the Mexican Stock Exchange declaring a cash dividend of $0.196080 Mexican pesos per share on its common stock representing a total amount of $200,001,600.00 M.N., payable to shareholders of record of the applicable circulating shares at the close of business on December 27, 2023.

• Genomma Lab Internacional Reports Third Quarter 2023 Results

  10/25/2023

  Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma Lab" or "the Company"), today announced its results for the third quarter ended September 30, 2023. 

• Genomma Lab Internacional S.A.B. de C.V. Third Quarter 2023 Earnings Results Conference Call

  10/4/2023

  Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company") today announced that it will report its Third Quarter 2023 results on Wednesday, October 25, 2023, after the Mexican Market (BMV) close.

• Genomma Lab Internacional Announces Fifth Dividend Payment

  9/20/2023

  Genomma Lab Internacional, S.A.B. de C.V. informs that the Company filed a Notice of Rights with the Mexican Stock Exchange declaring a cash dividend of $0.196080 Mexican pesos per share on its common stock representing a total amount of $ 200,001,600.00 M.N., payable to shareholders of record at the close of business on September 29, 2023.

• Genomma Lab Internacional Informs the Voluntarily Prepayment of the Second Tranche of Its IFC Secured Loan

  8/8/2023

  Genomma Lab Internacional, S.A.B. de C.V., one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, announced that on August 04, 2023 it has voluntarily prepaid the total amortization for the second tranche of its IFC secured loan.

• Genomma Lab Manufacturing Facility Granted Cofepris Operating License for All Its Pharma / OTC Manufacturing Lines

  8/7/2023

  Genomma Lab Internacional, S.A.B. de C.V. announced that the Mexican Ministry of Health's Federal Committee for Protection from Sanitary Risks has granted its approval of the sanitary license for the oral liquids, topical liquids and tablet coatings operations at Genomma Lab's Medicinas y Medicamentos Nacionales, S.A. de C.V. manufacturing facility in the State of Mexico.

• Genomma Lab Internacional Reports Second Quarter 2023 Results

  7/26/2023

  Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma Lab" or "the Company"), today announced its results for the second quarter ended June 30, 2023. 

• Genomma Lab Announces Second Quarter 2023 Financial Results Call and Webcast

  7/6/2023

  Genomma Lab Internacional, S.A.B. de C.V., announced that it will report its Second Quarter 2023 results on Wednesday, July 26, 2023 after the Mexican Market close.

• Genomma Lab Internacional Announces Fourth Dividend Payment

  6/2/2023

  Genomma Lab Internacional, S.A.B. de C.V. informs that the Company filed a Notice of Rights with the Mexican Stock Exchange declaring a cash dividend of $0.196080 Mexican pesos per share on its common stock representing a total amount of $ 200,001,600.00 M.N., payable to shareholders of record at the close of business on June 7th, 2023.

• Genomma Lab Internacional Reports First Quarter 2023 Results

  4/27/2023

  Genomma Lab Internacional, S.A.B. de C.V., announced its results for the first quarter ended March 31, 2023.

• Genomma Lab Announces First Quarter 2023 Financial Results Call and Webcast

  4/10/2023

  Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company"), today announced that it will report its First Quarter 2023 results on Wednesday, April 26, 2023 after the Mexican Market (BMV) close.

• Genomma Lab Internacional Reports Fourth Quarter & Full Year 2022 Results

  2/22/2023

  Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma Lab" or "the Company"), today announced its results for the fourth quarter and full year ended December 31, 2022.

• Genomma Lab Announces Fourth Quarter & Full Year 2022 Financial Results Call and Webcast

  1/30/2023

  Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company"), today announced that it will report its Fourth Quarter & Full Year 2022 results on Wednesday, February 22, 2023 after the Mexican Market (BMV) close.

• IFC and Genomma Lab signed a Multi-currency Long-term Loan to Boost Access to OTC Medicines in Latin America and the Caribbean Region

  1/9/2023

  To increase access to high quality and affordable medicines in Latin America and the Caribbean Region and address the impact of the COVID-19 pandemic at a global scale, IFC is providing a US$60 million multi-currency long-term loan to Genomma Lab Internacional, S.A.B. de C.V., a leading pharmaceutical company based in Mexico.

• Genomma Lab to Host Investor Day and Site Visit on March 8, 2023 in Mexico

  12/20/2022

  Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company"), one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, will host its Investor Day and Site Visit ("Genomma Day") on Wednesday, March 8, 2023 in Mexico.

• Genomma Lab Internacional Announces Leadership Succession Plan

  11/28/2022

  Genomma Lab Internacional, S.A.B. de C.V. announces a leadership succession plan that positions the Company to continue driving profitable growth and delivering on the Company's vision, as CEO Jorge Brake has informed the Board of his intention to transition from the CEO role while maintaining active involvement in the Company's future.